Cefbuperazone (CBPZ) の前立腺組織内移行に関する検討

Abstract

TUR-Pによって治療を行った前立腺肥大症患者23例に対してCBPZ 1 gまたは2 gを静注し, 1時間後の血清, 前立腺組織内濃度について検討した.1) CBPZ投与後の血清および前立腺組織内濃度はその投与量により, 良好なdose responceを示した.2)切除前立腺重量と前立腺組織内濃度には有意な相関関係はなかった.3)前立腺組織内濃度と臨床分離株に対するCBPZのMIC 80との比較により, グラム陰性桿菌が起炎菌である大半の細菌性前立腺炎や前立腺肥大症術後などに治療効果が十分期待できると思われた

The concentration of Cefbuperazone (CBPZ) was determined in the prostatic tissue and serum of 23 patients with benign prostatic hypertrophy. One or 2 of CBPZ was injected intravenously prior to transurethral prostatectomy. The mean CBPZ level in prostatic tissue and tissue/serum ratio at 1 hour was 17.4 +/- 7.2 micrograms/g (28.9 +/- 9.1%) in 10 patients administered 1 g of CBPZ, and 34.7 +/- 1C.2 micrograms/g (35.7 +/- 13.2%) in 13 patients administered 2 g of CBPZ. Serum and prostatic tissue CBPZ levels responded satisfactorily to the dose of CBPZ. Weights of resected prostatic tissue were not correlated to the tissue CBPZ level. Judging from the inhibitory concentration of CBPZ (minimum inhibitory concentration 80), the prostatic tissue CBPZ level was sufficient against pathogenic bacteria, particularly E. coli, K. pneumoiae and P. mirabilis for a relatively long time. For this reason CBPZ is a very useful drug for treatment of bacterial prostatitis and postoperative infection of prostate.